Smith+Nephew saw gains in its fourth quarter and full-year revenue, according to financial results posted March 2.
Six things to know:
1. Full year revenue was $6.2 billion, up 6.1% compared to 2024.
2. Orthopedic revenue was $2.4 billion in 2025, a 5.7% increase year over year. Within that segment, knee sales were $1 billion, hip sales were $641 million, reconstruction sales were $136 million and trauma sales were $649 million.
3. Sports medicine and ENT revenue reached $1.9 billion, growing 6% year over year. Sports medicine and joint repair saw the lion’s share of sales in that category with $1 billion. Arthroscopic enabling technologies grew 2.4% year over year with $647 million, and ENT sales were $220 million.
4. Fourth-quarter sales were $1.7 billion, an 8.3% increase year over year.
5. Smith+Nephew expects 2026 sales to grow 6%.
6. “I am pleased that a strong fourth quarter helped us meet or exceed our 2025 targets
for revenue growth, profitability and cash generation,” CEO Deepak Nath, said in the release. “During the year, newer products drove strong broad-based performance, with underlying revenue growth above 5% for all three business units, and we look forward to a strong cadence of further new product introductions in 2026.”
